{"id":"W2912094423","doi":"10.1200/jco.2019.37.4_suppl.327","title":"Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Hepatocellular carcinoma; Sorafenib; Gastroenterology; Cancer; Progressive disease; Clinical endpoint; Clinical trial; Oncology; Immunotherapy; Disease","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004500324,0.0002058737,0.000377211,0.0001438268,0.0001762413,0.000433105,0.0002166806,0.0002914415,0.0020741],"category_scores_gemma":[0.0005686732,0.000119234,0.0004312601,0.0002986151,0.0001662882,0.0002699595,0.0002803467,0.0006118699,0.0003839047],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000526246,"about_ca_system_score_gemma":0.0005455332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001193842,"about_ca_topic_score_gemma":0.002743611,"domain_scores_codex":[0.9998955,0.00003446778,0.000009184839,0.00002695543,0.00001447882,0.00001949327],"domain_scores_gemma":[0.9996916,0.00005110377,0.0001008125,0.00001825647,0.00001747708,0.0001207739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2453704,0.005679479,0.4451002,0.00162505,0.00130712,0.001188038,0.0003076301,0.00340799,0.0321723,0.0002699654,0.01668584,0.2468859],"study_design_scores_gemma":[0.04529716,0.1316669,0.7759082,0.0002402007,0.001410578,0.002955872,0.0002062058,0.004446549,0.008191429,0.0003156931,0.02930511,0.00005599662],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944718,0.002016516,0.0001594231,0.0001568499,0.00002969772,0.0002206294,0.001310648,0.00002007536,0.001614462],"genre_scores_gemma":[0.9953577,0.0007602407,0.0004043396,0.0003104291,0.00003499175,0.0001957652,0.002267318,0.000004371986,0.000664887],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0020741,"threshold_uncertainty_score":0.006938517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0299375002869407,"score_gpt":0.3545736872949904,"score_spread":0.3246361870080497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}